A double-blind, randomized, placebo-controlled, multiple-dose, multi-centre safety and efficacy study of co-administration of tesofensine/metoprolol in subjects with Prader-Willi syndrome (PWS).

Trial Profile

A double-blind, randomized, placebo-controlled, multiple-dose, multi-centre safety and efficacy study of co-administration of tesofensine/metoprolol in subjects with Prader-Willi syndrome (PWS).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs Metoprolol/tesofensine (Primary)
  • Indications Prader-Willi syndrome
  • Focus Therapeutic Use
  • Sponsors Saniona
  • Most Recent Events

    • 26 Oct 2017 Dr. Torok in Hungary is a primary investigator of this trial, as reported in a Saniona media release.
    • 26 Oct 2017 Interim results published in the Saniona Media Release
    • 26 Oct 2017 The company is planning to un-blind the study and analyse data on individual patients drug exposure in relation to observed efficacy and safety signals of this trial to decide the fate of Tesomet in Prader-Willi syndrome, as reported in a Saniona media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top